Effect of Physical Activity Program on Sedentary of Patients With Upper Aerodigestive Tract Cancer
Launched by CENTRE HOSPITALIER DE VALENCE · Dec 15, 2023
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The APAORL2 study is a clinical trial designed to see if a special physical activity program can help patients with upper aerodigestive tract cancer become more active and less sedentary over an 18-month period. This means the researchers want to find out if regular exercise can improve the physical health and well-being of patients who are recovering from this type of cancer.
To participate in this study, you need to be at least 18 years old and have a newly diagnosed, non-spreading form of upper aerodigestive tract cancer. You should also have a good chance of living for at least 18 months and have access to a smartphone, tablet, or computer with the internet for remote exercise sessions. If you have any health issues that prevent you from doing moderate exercise or if there are other reasons that would make it hard for you to take part in the study, you may not be eligible. If you join, you can expect to be part of a supportive program that encourages you to stay active while receiving care for your cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients ≥18 years
- • newly diagnosed, histologically proven Upper Aerodigestive Tract Cancer, non-metastatic,
- • life expectancy ≥18 months
- • having a smartphone, tablet or computer with an internet connection enabling remote physical Activity sessions for the experimental group
- Exclusion Criteria:
- • Presenting a contraindication to moderate physical activity
- • Deprived of their liberty by court or administrative decision
- • Unable to be followed for medical, social, family, geographic or psychological reasons for the duration of the study,
About Centre Hospitalier De Valence
Centre Hospitalier de Valence is a leading healthcare institution dedicated to advancing medical research and patient care through innovative clinical trials. With a strong commitment to enhancing treatment options and improving patient outcomes, the center collaborates with multidisciplinary teams of healthcare professionals and researchers. It focuses on a wide range of therapeutic areas, leveraging state-of-the-art facilities and a patient-centered approach to ensure ethical and efficient study conduct. By prioritizing safety and scientific rigor, Centre Hospitalier de Valence aims to contribute significantly to the evolving landscape of healthcare and medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Guillaume Guillaume
Principal Investigator
CH VALENCE
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported